rhVEGF treatment preserves pulmonary vascular reactivity and structure in an experimental model of pulmonary hypertension in fetal sheep

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 289, Issue 2 33-2, 2005, Pages

  Grover, Theresa R ^a   Parker, Thomas A ^a   Markham, Neil E ^a   Abman, Steven H ^a  

^a Children's Hospital Colorado   (United States)

Author keywords

Angiogenesis; Persistent pulmonary hypertension of the newborn; Pulmonary development; Recombinant human vascular endothelial growth factor

Indexed keywords

8 BROMOGUANOSINE PHOSPHATE; ACETYLCHOLINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PEGAPTANIB; RECOMBINANT VASCULOTROPIN; SODIUM CHLORIDE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA PRESSURE; ARTERY WALL; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; DUCTUS ARTERIOSUS OBLITERATION; EXPERIMENTAL MODEL; FEMALE; FETUS; FROZEN SECTION; HEART LEFT ATRIUM PRESSURE; HISTOPATHOLOGY; LUNG ARTERY; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG BLOOD VESSEL; LUNG HEMODYNAMICS; NONHUMAN; PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN; PRESSURE TRANSDUCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SHEEP; SIGNAL TRANSDUCTION; THICKNESS; TISSUE REGENERATION; TISSUE STRUCTURE; UPREGULATION; VASCULAR ENDOTHELIUM; VASODILATATION; WESTERN BLOTTING;

ANIMALS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; FETUS; HYPERTENSION, PULMONARY; LUNG; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PREGNANCY; PULMONARY ARTERY; PULMONARY CIRCULATION; PULMONARY WEDGE PRESSURE; RECOMBINANT PROTEINS; SHEEP; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATION;

EID: 22444442100     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00038.2005     Document Type: Article

References (35)

1. Abman SH, Chatfield BA, Hall SL, and McMurtry IF. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol Lung Cell Mol Physiol 259: L1921-L1927, 1990.
2. Abmah SH, Shanley PF, and Accurso FJ. Failure of postnatal adaptation of the pulmonary circulation after chronic intrauterine pulmonary hypertension in fetal lambs. J Clin Invest 83: 1849-1858, 1989.
3. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, and Isner JM. Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor. Circulation 91: 2802-2809, 1995.
4. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N Symes JF, and Isner JM. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg 21:314-325,1995.
5. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declerq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439, 1996.
6. Ferrara N and Hanzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161: 851-858, 1989.
7. Ferrara N, Houck KA, Jakeman LB, Winer J, and Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47: 211-218, 1991.
8. Ferrera N, Carver-Moore KC, Hen H, Dowd M, Lu L, O'Shea DK, Powell-Braxton LP, Hillan KF, and Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 435-442, 1996.
9. Garg UC and Hassid A. NO-generating vasodilators and 8BrGMP inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83: 1774, 1989.
10. Grover TR, Parker TA, Zenge JP, Markham NE, Kinsella JP, and Abman SH. Intrauterine pulmonary hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284: L508-L517, 2003.
11. Grover TR, Zenge JP, Parker TA, and Abman SH. Vascular endothelial growth factor causes pulmonary vasodilation through activation of the phosphatidylinositol-3-kinase-nitric oxide pathway in the late-gestation ovine fetus. Pediatr Res 52: 907-912, 2002.
12. Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, Law PY, and Gebbel RP. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 247: 495-504, 1999.
13. Harada K, Friedman M, Lopez JJ, Wang SY, Li J, Prasad PV, Pearlman JD, Edelman ER, Sellke FW, and Simons M. Vascular endothelial growth factor in chronic myocardial ischemia. Am J Physiol Heart Circ Physiol 270: H1791-H1802, 1996.
14. Hariawala MD, Horowitz JR, Esakof DD, Sheriff DD, Walter DH, Keyt B, Isner JM, and Symes JF. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 63: 77-82, 1996.
15. Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, Chaudhry M, Symes JF, and Isner JM. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Arterioscler Thromb Vasc Biol 17: 2793-2800, 1997.
16. Keyt BA, Berleau L, Nguyen HV, Chen H, Hinsohn H, Vandlen R, and Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271: 7788-7795, 1996.
17. Kinsella JP and Abman SH. Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn. J Pediatr 126: 853-864, 1995.
18. Kroll J and Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 252: 743-746, 1998.
19. Le Cras TD, Markham NE, Tuder RM, Voelkel NF, and Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol 282: L555-L562, 2002.
20. Le Cras TD, Xue C, Rengasamy A, and Johns RA. Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am J Physiol Lung Cell Mol Physiol 270: L164-L170, 1996.
21. Leung DW, Cacianes G, Kuang WJ, Goedel DV, and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989.
22. Levin DL, Heymann MA, Kitterman JA, Gregory GA, Phibbs RH, and Rudolph AM. Persistent pulmonary hypertension of the newborn infant. J Pediatr 89: 626-630, 1976.
23. Lewis AB, Heymann MA, and Rudolph AM. Gestational changes in pulmonary vascular responses in fetal lambs in utero. Circ Res 39: 536-541, 1976.
24. Lopez JJ, Laham RJ, Carrozza JP, Tofukuji M, Sellke FW, Bunting S, and Simons M. Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am J Physiol Heart Circ Physiol 273: H1317-H1323, 1997.
25. Lui W, Ahmad SA, Reinmuth N, Shaheen RM, Sung YD, Fan F, and Ellis LM. Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 5: 323-328, 2000.
26. McQueston JA, Kinsella JK, Ivy DD, McMurtry IF, and Abman SH. Chronic pulmonary hypertension in utero impairs endothelium-dependent vasodilation. Am J Physiol Heart Circ Physiol 268: H288-H294, 1995.
27. Murphy JD, Rabinovitch M, Goldstein JD, and Reid LM. The structural basis of persistent pulmonary hypertension of the newborn infant. J Pediatr 98: 962-967, 1981.
28. Sato K, Wu T, Laham RJ, Johnson RB, Douglas P, Li J, Sellke FW, Bunting S, Simons M, and Post MJ. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol 37: 616-623, 2001.
29. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, and Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 2004.
30. Spinella F, Rosano L, Di Castro V, Natali PG, and Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1α in ovarian carcinoma cells. J Biol Chem 277: 27850-27855, 2002.
31. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, and Isner JM. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93: 662-670, 1994.
32. Tilton RG, Chang KC, Lejeune WS, Stephan CC, Brock TA, and Williamson JR. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci 40: 689-696, 1999.
33. Villanueva ME, Zaher FM, Svinarich DM, and Konduri GG. Decreased gene expression of endothelial nitric oxide synthase in newborns with persistent pulmonary hypertension. Pediatr Res 44: 338-343, 1998.
34. Wheeler-Jones C, Abu-Ghazaleh R, Cospedal R, Houliston RA, Martin J, and Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase-A2 in endothelial cells via p42/p44 mitogen activated protein kinases. FEBS Lett 420: 28-32, 1997.
35. Ziegler JW, Ivy DD, Kinsella JP, and Abman SH. The role of nitric oxide, endothelin, and prostaglandins in the transition of the pulmonary circulation. Clin Perinatol 22: 387-403, 1995.